SYNERGY Early Stent Thrombosis

descriptionPublicationkeyboard_double_arrow_right Article 01 Nov 2019 English Publisher:Elsevier BVJournal:JACC: Cardiovascular Interventions, volume 12, pages 2,227-2,228 (issn: 1936-8798,

Copyright policy )

Authors: Dean J, Kereiakes; Juan F, Granada;

doi: 10.1016/j.jcin.2019.09.009

pmid: 31699381

SYNERGY Early Stent Thrombosis

- Summary
- Subjects
- Metrics

Abstract

SYNERGY (Boston Scientific, Marlborough, Massachusetts), the first metallic bioresorbable polymer drug-eluting stent (DES) approved by the U.S. Food and Drug Administration, incorporates design elements intended to expedite stent healing and enhance safety [(1)][1]. Thus, the report of SYNERGY

Keywords

Treatment Outcome, Polymers, Humans, Drug-Eluting Stents, Thrombosis, Everolimus

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	0
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average